Abstract：
OBJECTIVE: The objective of this systematic review and meta-analysis was to estimate the global prevalence of multi-drug resistant (MDR) Pseudomonas aeruginosa causing ventilator-associated pneumonia (VAP).
METHODS: The systematic search was conducted in four databases. Original studies describing MDR P. aeruginosa VAP prevalence in adults from 2012- 2022 were included. A meta-analysis, using the random effects model, was conducted for overall, subgroups (country, published year, study duration, and study design), and European data, respectively. Univariate meta-regression based on pooled estimates was also conducted. Systematic review registered in International Prospective Register of Systematic Review (CRD42022384035).
RESULTS: In total of 31 studies, containing a total of 7951 cases from 16 countries, were included. The overall pooled prevalence of MDR among P. aeruginosa causing VAP was 33% (95% confidence interval [CI] 27.7-38.3%). The highest prevalence was for Iran at 87.5% (95% CI 69-95.7%), and the lowest was for the USA at 19.7% (95% CI 18.6-20.7%). The European prevalence was 29.9% (95% CI 23.2-36.7%).
CONCLUSIONS: This review indicates that the prevalence of MDR P. aeruginosa in patients with VAP is generally high and varies significantly between countries; however, data are insufficient for many countries. The data in this study can provide a reference for VAP management and drug customisation strategies.
METHODS: The systematic search was conducted in four databases. Original studies describing MDR P. aeruginosa VAP prevalence in adults from 2012- 2022 were included. A meta-analysis, using the random effects model, was conducted for overall, subgroups (country, published year, study duration, and study design), and European data, respectively. Univariate meta-regression based on pooled estimates was also conducted. Systematic review registered in International Prospective Register of Systematic Review (CRD42022384035).
RESULTS: In total of 31 studies, containing a total of 7951 cases from 16 countries, were included. The overall pooled prevalence of MDR among P. aeruginosa causing VAP was 33% (95% confidence interval [CI] 27.7-38.3%). The highest prevalence was for Iran at 87.5% (95% CI 69-95.7%), and the lowest was for the USA at 19.7% (95% CI 18.6-20.7%). The European prevalence was 29.9% (95% CI 23.2-36.7%).
CONCLUSIONS: This review indicates that the prevalence of MDR P. aeruginosa in patients with VAP is generally high and varies significantly between countries; however, data are insufficient for many countries. The data in this study can provide a reference for VAP management and drug customisation strategies.
摘要：
目的：本系统综述和荟萃分析的目的是评估导致呼吸机相关性肺炎（VAP）的多重耐药（MDR）铜绿假单胞菌的全球患病率。
方法：在四个数据库中进行系统检索。纳入2012年至2022年成人MDR铜绿假单胞菌VAP患病率的原始研究。Meta分析,使用随机效应模型，是为整体进行的，子组(国家，发表年,研究持续时间，和研究设计)，欧洲数据,分别。还进行了基于汇总估计的单变量荟萃回归。在PROSPERO注册的系统评价(CRD42022384035)。
结果：31项研究，共有来自16个国家的7,951例,包括在内。导致VAP的铜绿假单胞菌中MDR的总体合并患病率为33％（95％CI27.7％-38.3％）。患病率最高的是伊朗87.5%（95%CI69%-95.7%），最低的是美国19.7%（95%CI18.6%-20.7%）。欧洲患病率为29.9%（95%CI23.2%-36.7%）。
结论：本综述表明，在VAP患者中，MDR铜绿假单胞菌的患病率普遍较高，且各国之间差异显著，然而，许多国家的数据不足。本研究数据可为VAP管理和药物定制策略提供参考。
方法：在四个数据库中进行系统检索。纳入2012年至2022年成人MDR铜绿假单胞菌VAP患病率的原始研究。Meta分析,使用随机效应模型，是为整体进行的，子组(国家，发表年,研究持续时间，和研究设计)，欧洲数据,分别。还进行了基于汇总估计的单变量荟萃回归。在PROSPERO注册的系统评价(CRD42022384035)。
结果：31项研究，共有来自16个国家的7,951例,包括在内。导致VAP的铜绿假单胞菌中MDR的总体合并患病率为33％（95％CI27.7％-38.3％）。患病率最高的是伊朗87.5%（95%CI69%-95.7%），最低的是美国19.7%（95%CI18.6%-20.7%）。欧洲患病率为29.9%（95%CI23.2%-36.7%）。
结论：本综述表明，在VAP患者中，MDR铜绿假单胞菌的患病率普遍较高，且各国之间差异显著，然而，许多国家的数据不足。本研究数据可为VAP管理和药物定制策略提供参考。
